Cryogenic Solutions Inc. Makes Announcement.HOUSTON--(BUSINESS WIRE)--April 22, 1999-- Cryogenic Solutions Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CYGS) has begun shipping beta test A test of new or revised hardware or software that is performed by users at their facilities under normal operating conditions. Beta testing follows alpha testing. Vendors of packaged software often offer their customers the opportunity of beta testing new releases or versions, and the kits of the company's proprietary ssDNA intracellular expression vector expression vector n. A vector, such as a plasmid, yeast, or animal virus genome, used to introduce foreign genetic material into a host cell in order to replicate and amplify the foreign DNA sequences as a recombinant molecule. . So far, kits have been delivered to Yale University School of Medicine; Washington University in St Louis, Department of Cell Biology; and The Research Foundation of SUNY SUNY - State University of New York , Syracuse. The beta kits are ready for shipment to other investigators pending material transfer agreements from the universities and other research facilities. CYGS will soon be posting Requests for Proposals on its website, www.cygs.net. The RFP's will suggest a variety of studies the company wants to pursue in addition to the beta tests already scheduled and the primate studies beginning at the Southwest Foundation for Biological Research. The purpose of the in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. studies is to demonstrate the ability of the ssDNA expression vector to synthesize any selected oligonucleotide sequence in the nuclei of a wide variety of targeted cell types. All proposals will be submitted to the CYGS Scientific Advisory Board for evaluation and approval. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion